No Improvement in OS or PFS from Sacituzumab Govitecan Compared with Chemotherapy In Pretreated Patients with Advanced Urothelial Cancer By Ogkologos - March 24, 2025 846 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the TROPiCS-04 study Source RELATED ARTICLESMORE FROM AUTHOR New Targeted Therapy Shows Promising Early Results in Advanced Pancreatic Cancer FDA Approves Pivekimab Sunirine-pvzy for Blastic Plasmacytoid Dendritic Cell Neoplasm, an Ultra-Rare Haematologic Malignancy Ivonescimab Plus Chemotherapy Improves OS Compared with Tislelizumab Plus Chemotherapy in Previously Untreated Patients with Advanced Squamous NSCLC MOST POPULAR FDA Grants Traditional Approval to Tarlatamab-dlle for Extensive Stage Small Cell... January 22, 2026 EMA Recommends Granting a Marketing Authorisation for Tebentafusp March 31, 2022 FDA Approves Belzutifan for Advanced Renal Cell Carcinoma January 19, 2024 Patient Guide in Testicular Cancer Now Available Also in German January 14, 2026 Load more HOT NEWS Finding Hope During Cancer and Pregnancy: “Your Stories” Podcast Treatment with Tebentafusp Results in Longer Overall Survival Among Previously Untreated... Neoadjuvant Nivolumab Plus Ipilimumab Leads to a Pathological Response in a... Nivolumab/Ipilimumab Combination Should Precede Dual BRAF/MEK Inhibition in Patients with BRAF-Mutated...
